1535-45-1

Basic information

• Product Name: 3-(aminosulfonyl)-4-fluorobenzoic acid
• Synonyms: 3-(aminosulfonyl)-4-fluorobenzoic acid
• CAS NO: 1535-45-1
• Molecular Formula: C₇H₆FNO₄S
• Molecular Weight: 219.19
• Mol File: 1535-45-1.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(aminosulfonyl)-4-fluorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(aminosulfonyl)-4-fluorobenzoic acid(1535-45-1)
• EPA Substance Registry System: 3-(aminosulfonyl)-4-fluorobenzoic acid(1535-45-1)

Safety Data

• Hazardous Substances Data: 1535-45-1(Hazardous Substances Data)

Usage

General Description

3-(aminosulfonyl)-4-fluorobenzoic acid is a chemical compound with the molecular formula C7H7NO4S. It is a derivative of benzoic acid containing a fluorine atom and an aminosulfonyl group. 3-(aminosulfonyl)-4-fluorobenzoic acid is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It exhibits biological activity and has been studied for its potential application in medicinal chemistry. The presence of the fluorine atom and the aminosulfonyl group in the molecule contributes to its unique properties and potential biological effects, making it an interesting compound for further research and development.

Upstream product

• 2267-40-5 3-chlorosulfonyl-4-fluoro-benzoic acid 
• 438539-71-0 2-fluoro-5-methylbenzenesulphonamide 
• 456-22-4 4-Fluorobenzoic acid 

Downstream Products

• 656-93-9 4-fluoro-3-sulphamoylbenzamide 
• 1204574-89-9 methyl 4-cyclopropylamino-3-sulphamoylbenzoate 
• 1110781-81-1 4-fluoro-N-(3-methoxy-phenyl)-3-sulfamoyl-benzamide 

Relevant articles and documents

Synthesis of a new series of 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides as carbonic anhydrase I, II, IV and IX inhibitors

The synthesis of a novel series of 3-functionalised benzenesulfonamides incorporating phenyl-1,2,3-triazole with an amide linker was achieved by using the “click-tail” approach. The new compounds, including the intermediates, were assayed as inhibitors of human carbonic anhydrase (CA, EC 4.2.1.1) isoforms hCA I and II (cytosolic isoforms) and also for hCA IV and IX (transmembrane isoforms) taking acetazolamide as standard drug. Most of these compounds exhibited excellent activity against all these isoforms. hCA I was inhibited with Kis in the range of 50.8–966.8 nM, while the glaucoma associated hCA II was inhibited with Kis in the range of 6.5–760.0 nM. Isoform hCA IV was inhibited with Kis in the range of 65.3–957.5 nM, whereas the tumor associated hypoxia induced hCA IX was inhibited with Kis in the range of 30.8–815.9 nM. The structure activity relationship study for the 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides against these isoforms was also inferred from the results.

Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidase-4 inhibitors

The optimization of a series of fused β-homophenylalanine inhibitors of dipeptidyl peptidase-4 (DPP-4) is described. Modification on the P2-binding moiety of 6 (IC50 = 10 nM) led to the discovery of β-homophenylalanine derivatives containing pyrrolidin-2-ylmethyl amides. The introduction of a sulfamine in the meta position of the phenyl ring improved the potency against DPP-4 (6-12-fold increase). Compound 14k showed DPP-4 inhibitory activity with an IC50 value of 0.87 nM. Meanwhile, in vivo experiments exhibited that 14h had an efficiency comparable to sitagliptin at the dose of 10 mg/kg.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).